Gold from the sea: Marine compounds as inhibitors of the hallmarks of cancer

Biotechnology Advances

Volumn 29, Issue 5, 2011, Pages 531-547

  Schumacher, Marc ^a   Kelkel, Mareike ^a   Dicato, Mario ^a   Diederich, Marc ^a  

^a LABORATOIRE DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE DU CANCER   (Luxembourg)

Author keywords

Cancer prevention; Cell death; Chemotherapy; Invasion; Marine antitumor compounds; Metastasis; Proliferation; Telomerase

Indexed keywords

ANTITUMOR COMPOUNDS; CANCER PREVENTION; INVASION; METASTASIS; PROLIFERATION; TELOMERASE;

CELL DEATH; CHEMOTHERAPY; PATHOLOGY; TISSUE;

DISEASES;

ANTINEOPLASTIC AGENT; BIOLOGICAL PRODUCT;

ADVANCED TECHNOLOGY; APOPTOSIS; BIOTECHNOLOGY; CANCER; CELL ORGANELLE; CHEMOTHERAPY; DISEASE CONTROL; INHIBITOR; MARINE ENVIRONMENT; MARINE TECHNOLOGY; RESEARCH WORK;

ANIMAL; APOPTOSIS; AQUATIC SPECIES; BIOTECHNOLOGY; CELL GROWTH; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECT; HUMAN; ISOLATION AND PURIFICATION; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; AQUATIC ORGANISMS; BIOLOGICAL PRODUCTS; BIOTECHNOLOGY; CELL GROWTH PROCESSES; DRUG DISCOVERY; HUMANS; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 79960802666     PISSN: 07349750     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biotechadv.2011.02.002     Document Type: Review

References (169)

1. Aichberger K.J., Mayerhofer M., Krauth M.T., Skvara H., Florian S., Sonneck K., et al. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. Blood 2005, 105:3303-3311.
2. Ainnslie R.D., Barchi J.J., Kuniyoshi M., Moore R.E., Myndersee J.S. Structure of malyngamide C. J Org Chem 1985, 50:2859-2862.
3. Andersson Y., Juell S., Fodstad O. Downregulation of the antiapoptotic MCL-1 protein and apoptosis in MA-11 breast cancer cells induced by an anti-epidermal growth factor receptor-Pseudomonas exotoxin a immunotoxin. Int J Cancer 2004, 112:475-483.
4. Austin P., Heller M., Williams D.E., McIntosh L.P., Vogl A.W., Foster L.J., et al. Release of membrane-bound vesicles and inhibition of tumor cell adhesion by the peptide neopetrosiamide A. PLoS ONE 2010, 5:e10836.
5. Bai R., Cichacz Z.A., Herald C.L., Pettit G.R., Hamel E. Spongistatin 1, a highly cytotoxic, sponge-derived, marine natural product that inhibits mitosis, microtubule assembly, and the binding of vinblastine to tubulin. Mol Pharmacol 1993, 44:757-766.
6. Blunt J.W., Copp B.R., Munro M.H., Northcote P.T., Prinsep M.R. Marine natural products. Nat Prod Rep 2010, 27:165-237.
7. Blunt J.W., Copp B.R., Munro M.H., Northcote P.T., Prinsep M.R. Marine natural products. Nat Prod Rep 2011, 28:196-268.
8. Boonananwong S., Kongkathip B., Kongkathip N. First synthesis of 3,16,20-polyoxygenated cholestanes, new cytotoxic steroids from the gorgonian Leptogorgia sarmentosa. Steroids 2008, 73:1123-1127.
9. Butler A.J., Rees T., Beesley P., Bax N.J. Marine biodiversity in the Australian region. PLoS ONE 2010, 5:e11831.
10. Carney J.R., Scheuer P.J., Kelly-Borges M., Makaluvamine G. A cytotoxic pigment from an an Indonesian Sponge Histodermella sp. Tetrahedron 1993, 49:8483-8486.
11. Catassi A., Cesario A., Arzani D., Menichini P., Alama A., Bruzzo C., et al. Characterization of apoptosis induced by marine natural products in non small cell lung cancer A549 cells. Cell Mol Life Sci 2006, 63:2377-2386.
12. Census of marine life http://wwwcomlorg/about-census.
13. Chan H., Bartos D.P., Owen-Schaub L.B. Activation-dependent transcriptional regulation of the human Fas promoter requires NF-kappaB p50-p65 recruitment. Mol Cell Biol 1999, 19:2098-2108.
14. Chilov D., Kukk E., Taira S., Jeltsch M., Kaukonen J., Palotie A., et al. Genomic organization of human and mouse genes for vascular endothelial growth factor C. J Biol Chem 1997, 272:25176-25183.
15. Cho J.H., Johnson G.V. Primed phosphorylation of tau at Thr231 by glycogen synthase kinase 3beta (GSK3beta) plays a critical role in regulating tau's ability to bind and stabilize microtubules. J Neurochem 2004, 88:349-358.
16. Cho-Vega J.H., Rassidakis G.Z., Admirand J.H., Oyarzo M., Ramalingam P., Paraguya A., et al. MCL-1 expression in B-cell non-Hodgkin's lymphomas. Hum Pathol 2004, 35:1095-1100.
17. Chung Y.C., Chang Y.F. Significance of inflammatory cytokines in the progression of colorectal cancer. Hepatogastroenterology 2003, 50:1910-1913.
18. Cipres A., O'Malley D.P., Li K., Finlay D., Baran P.S., Vuori K. Sceptrin, a marine natural compound, inhibits cell motility in a variety of cancer cell lines. ACS Chem Biol 2010, 5:195-202.
19. Ciucci A., Gianferretti P., Piva R., Guyot T., Snape T.J., Roberts S.M., et al. Induction of apoptosis in estrogen receptor-negative breast cancer cells by natural and synthetic cyclopentenones: role of the IkappaB kinase/nuclear factor-kappaB pathway. Mol Pharmacol 2006, 70:1812-1821.
20. Claudio E., Brown K., Park S., Wang H., Siebenlist U. BAFF-induced NEMO-independent processing of NF-kappa B2 in maturing B cells. Nat Immunol 2002, 3:958-965.
21. Colotta F., Allavena P., Sica A., Garlanda C., Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009, 30:1073-1081.
22. Conti M. Cyclopentenone: a special moiety for anticancer drug design. Anticancer Drugs 2006, 17:1017-1022.
23. Conti M. A perspective on rational drug design with cyclopentenone: targeting the proteome with the cyclopentenone chemical moiety. Expert Opin Drug Discovery 2007, 2:1153-1159.
24. Coope H.J., Atkinson P.G., Huhse B., Belich M., Janzen J., Holman M.J., et al. CD40 regulates the processing of NF-kappaB2 p100 to p52. EMBO J 2002, 21:5375-5385.
25. Coppola S., Ghibelli L. GSH extrusion and and the mitochondrial pathway of apoptotic signalling. Biochem Soc Trans 2000, 28:56-61.
26. Cuadrado A., Garcia-Fernandez L.F., Gonzalez L., Suarez Y., Losada A., Alcaide V., et al. Aplidin induces apoptosis in human cancer cells via glutathione depletion and sustained activation of the epidermal growth factor receptor, Src, JNK, and p38 MAPK. J Biol Chem 2003, 278:241-250.
27. D'Incalci M., Galmarini C.M. A review of trabectedin (ET-743): a unique mechanism of action. Mol Cancer Ther 2010, 9:2157-2163.
28. Daugan A., Grondin P., Ruault C., Le Monnier de Gouville A.C., Coste H., Linget J.M. The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 2: 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione analogues. J Med Chem 2003, 46:4533-4542.
29. Debatin K.M. Apoptosis pathways in cancer and cancer therapy. Cancer Immunol Immunother 2004, 53:153-159.
30. Degterev A., Boyce M., Yuan J. A decade of caspases. Oncogene 2003, 22:8543-8567.
31. Derenne S., Monia B., Dean N.M., Taylor J.K., Rapp M.J., Harousseau J.L., et al. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood 2002, 100:194-199.
32. Dong Z., Nemeth J.A., Cher M.L., Palmer K.C., Bright R.C., Fridman R. Differential regulation of matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1 (TIMP-1) and TIMP-2 expression in co-cultures of prostate cancer and stromal cells. Int J Cancer 2001, 93:507-515.
33. Du C., Fang M., Li Y., Li L., Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000, 102:33-42.
34. Dumontet C., Jordan M.A. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov 2010, 9:790-803.
35. Ebada S.S., Lin W., Proksch P. Bioactive sesterterpenes and triterpenes from marine sponges: occurrence and pharmacological significance. Mar Drugs 2010, 8:313-346.
36. Erba E., Bergamaschi D., Bassano L., Damia G., Ronzoni S., Faircloth G.T., et al. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur J Cancer 2001, 37:97-105.
37. Fautin D., Dalton P., Incze L.S., Leong J.A., Pautzke C., Rosenberg A., et al. An overview of marine biodiversity in United States waters. PLoS ONE 2010, 5:e11914.
38. FDA http://wwwfdagov/.
39. Fedorov S.N., Shubina L.K., Bode A.M., Stonik V.A., Dong Z. Dactylone inhibits epidermal growth factor-induced transformation and phenotype expression of human cancer cells and induces G1-S arrest and apoptosis. Cancer Res 2007, 67:5914-5920.
40. Fontana A., Cavaliere P., Ungur N., D'Souza L., Parameswaram P.S., Cimino G. New scalaranes from the nudibranch Glossodoris atromarginata and its sponge prey. J Nat Prod 1999, 62:1367-1370.
41. Frame S., Zheleva D. Targeting glycogen synthase kinase-3 in insulin signalling. Expert Opin Ther Targets 2006, 10:429-444.
42. Furstner A., Domostoj M.M., Scheiper B. Total syntheses of the telomerase inhibitors dictyodendrin B, C, and E. J Am Chem Soc 2006, 128:8087-8094.
43. Garrido L., Zubia E., Ortega M.J., Salva J. Isolation and structure elucidation of new cytotoxic steroids from the gorgonian Leptogorgia sarmentosa. Steroids 2000, 65:85-88.
44. Ghavami S., Hashemi M., Ande S.R., Yeganeh B., Xiao W., Eshraghi M., et al. Apoptosis and cancer: mutations within caspase genes. J Med Genet 2009, 46:497-510.
45. Ghosh S., May M.J., Kopp E.B. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998, 16:225-260.
46. Giono L.E., Manfredi J.J. The p53 tumor suppressor participates in multiple cell cycle checkpoints. J Cell Physiol 2006, 209:13-20.
47. Gradishar W.J. The place for eribulin in the treatment of metastatic breast cancer. Curr Oncol Rep 2011, 13:11-16.
48. Grant S., Roberts J.D. The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy. Drug Resist Updat 2003, 6:15-26.
49. Guittat L., De Cian A., Rosu F., Gabelica V., De Pauw E., Delfourne E., et al. Ascididemin and meridine stabilise G-quadruplexes and inhibit telomerase in vitro. Biochim Biophys Acta 2005, 1724:375-384.
50. Gullett N.P., Ruhul Amin A.R., Bayraktar S., Pezzuto J.M., Shin D.M., Khuri F.R., et al. Cancer prevention with natural compounds. Semin Oncol 2010, 37:258-281.
51. Guzman E.A., Johnson J.D., Linley P.A., Gunasekera S.E., Wright A.E. A novel activity from an old compound: manzamine A reduces the metastatic potential of AsPC-1 pancreatic cancer cells and sensitizes them to TRAIL-induced apoptosis. Invest New Drugs 2010.
52. Hamann M., Alonso D., Martin-Aparicio E., Fuertes A., Perez-Puerto M.J., Castro A., et al. Glycogen synthase kinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of the manzamine alkaloids. Potential for Alzheimer's disease. J Nat Prod 2007, 70:1397-1405.
53. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
54. Hassan H.M., Khanfar M.A., Elnagar A.Y., Mohammed R., Shaala L.A., Youssef D.T., et al. Pachycladins A-E, prostate cancer invasion and migration inhibitory Eunicellin-based diterpenoids from the red sea soft coral Cladiella pachyclados. J Nat Prod 2010, 73:848-853.
55. Haven G.T., Krzemien J.R., Nguyen T.T. Study of a renal microsomal inhibitor of hepatic cholesterol synthesis in intact cell systems. Res Commun Chem Pathol Pharmacol 1973, 6:253-262.
56. Hayward M.M., Roth R.M., Duffy K.J., Dalko P.I., Stevens K.L., Guo J., et al. Total synthesis of Altohyrtin A (Spongistatin 1): part 2**. Angew Chem Int Ed 1998, 37:192-196.
57. Hinterding K., Knebel A., Herrlich P., Waldmann H. Synthesis and biological evaluation of aeroplysinin analogues: a new class of receptor tyrosine kinase inhibitors. Bioorg Med Chem 1998, 6:1153-1162.
58. Hiroishi S., Sugie K., Yoshida T., Morimoto J., Taniguchi Y., Imai S., et al. Antitumor effects of Marginisporum crassissimum (Rhodophyceae), a marine red alga. Cancer Lett 2001, 167:145-150.
59. Hoang H., LaBarbera D.V., Mohammed K.A., Ireland C.M., Skibo E.B. Synthesis and biological evaluation of imidazoquinoxalinones, imidazole analogues of pyrroloiminoquinone marine natural products. J Med Chem 2007, 50:4561-4571.
60. Hsiang C.H., Straus D.S. Cyclopentenone causes cell cycle arrest and represses cyclin D1 promoter activity in MCF-7 breast cancer cells. Oncogene 2002, 21:2212-2226.
61. Huang Y., Park Y.C., Rich R.L., Segal D., Myszka D.G., Wu H. Structural basis of caspase inhibition by XIAP: differential roles of the linker versus the BIR domain. Cell 2001, 104:781-790.
62. Hunter A.M., LaCasse E.C., Korneluk R.G. The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis 2007, 12:1543-1568.
63. Iademarco M.F., McQuillan J.J., Rosen G.D., Dean D.C. Characterization of the promoter for vascular cell adhesion molecule-1 (VCAM-1). J Biol Chem 1992, 267:16323-16329.
64. Igney F.H., Krammer P.H. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2002, 2:277-288.
65. Inman W.D., Bray W.M., Gassner N.C., Lokey R.S., Tenney K., Shen Y.Y., et al. A beta-carboline alkaloid from the Papua New Guinea marine sponge Hyrtios reticulatus. J Nat Prod 2010, 73:255-257.
66. Ishida K., Ishibashi M., Shigemori H., Sasaki T., Kobayashi J., Agelasine G. a new antileukemic alkaloid from the Okinawan marine sponge Agelas sp. Chem Pharm Bull (Tokyo) 1992, 40:766-767.
67. Johnson K.A., Brown P.H. Drug development for cancer chemoprevention: focus on molecular targets. Semin Oncol 2010, 37:345-358.
68. Jones R.J., Sharkis S.J., Miller C.B., Rowinsky E.K., Burke P.J., May W.S. Bryostatin 1, a unique biologic response modifier: anti-leukemic activity in vitro. Blood 1990, 75:1319-1323.
69. Kanegawa K., Harada H., Myouga H., Katakura Y., Shirahata S., Kamei Y. Telomerase inhibiting activity in vitro from natural resources, marine algae extracts. Cytotechnology 2000, 33:221-227.
70. Karin M., Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 2000, 18:621-663.
71. Kazlauskas R., Murphy P.T., Quinn R.J., Wells R.J. Heteronemin, a new scalarin type sesterterpene from the sponge image. Tetrahedron Lett 1976, 17:2631-2634.
72. Keifer P.A., Schwartz R.E., Koker M.E.S., Hughes R.G.J., Rittschof D., Rinehart K.L. Bioactive bromopyrrole metabolites from the Caribbean sponge Agelas conifera. J Org Chem 1991, 56:2965-2975.
73. Khanfar M.A., El Sayed K.A. Phenylmethylene hydantoins as prostate cancer invasion and migration inhibitors. CoMFA approach and QSAR analysis. Eur J Med Chem 2010, 45:5397-5405.
74. Khanfar M.A., Youssef D.T., El Sayed K.A. Semisynthetic latrunculin derivatives as inhibitors of metastatic breast cancer: biological evaluations, preliminary structure-activity relationship and molecular modeling studies. Chem Med Chem 2010, 5:274-285.
75. Klotz T., Bloch W., Jacobs G., Niggemann S., Engelmann U., Addicks K. Immunolocalization of inducible and constitutive nitric oxide synthases in human bladder cancer. Urology 1999, 54:416-419.
76. Kobayashi J., Tsuda M., Murayama T., Nakamura H., Ohizumi Y., Ishibashi M., et al. Ageliferins, potent actomyosin ATPase activators from the Okinawan marine sponge Agelas sp. Tetrahedron 1990, 46:5579-5586.
77. Kuznetsov G., TenDyke K., Towle M.J., Cheng H., Liu J., Marsh J.P., et al. Tubulin-based antimitotic mechanism of E7974, a novel analogue of the marine sponge natural product hemiasterlin. Mol Cancer Ther 2009, 8:2852-2860.
78. Kuznetsov G., Towle M.J., Cheng H., Kawamura T., TenDyke K., Liu D., et al. Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res 2004, 64:5760-5766.
79. Kwan J.C., Teplitski M., Gunasekera S.P., Paul V.J., Luesch H. Isolation and biological evaluation of 8-epi-malyngamide C from the Floridian marine cyanobacterium Lyngbya majuscula. J Nat Prod 2010, 73:463-466.
80. Labarbera D.V., Skibo E.B. Synthesis of imidazo[1,5,4-de]quinoxalin-9-ones, benzimidazole analogues of pyrroloiminoquinone marine natural products. Bioorg Med Chem 2005, 13:387-395.
81. Lazebnik Y. What are the hallmarks of cancer?. Nat Rev Cancer 2010, 10:232-233.
82. Leal J.F., Garcia-Hernandez V., Moneo V., Domingo A., Bueren-Calabuig J.A., Negri A., et al. Molecular pharmacology and antitumor activity of Zalypsis in several human cancer cell lines. Biochem Pharmacol 2009, 78:162-170.
83. Ledroit V., Debitus C., Ausseil F., Raux R., Menou J.L., Hill B.T. Heteronemin as a protein farnesyl transferase inhibitor. Pharm Biol 2004, 42:454-456.
84. Lee K.H., Hall I.H., Mar E.C., Starnes C.O., ElGebaly S.A., Waddell T.G., et al. Sesquiterpene antitumor agents: inhibitors of cellular metabolism. Science 1977, 196:533-536.
85. Lee N.Y., Ermakova S.P., Zvyagintseva T.N., Kang K.W., Dong Z., Choi H.S. Inhibitory effects of fucoidan on activation of epidermal growth factor receptor and cell transformation in JB6 Cl41 cells. Food Chem Toxicol 2008, 46:1793-1800.
86. Li W., Srinivasula S.M., Chai J., Li P., Wu J.W., Zhang Z., et al. Structural insights into the pro-apoptotic function of mitochondrial serine protease HtrA2/Omi. Nat Struct Biol 2002, 9:436-441.
87. Lin X., Liu M., Hu C., Liao D.J. Targeting cellular proapoptotic molecules for developing anticancer agents from marine sources. Curr Drug Targets 2010, 11:708-715.
88. Ling Y.H., Aracil M., Jimeno J., Perez-Soler R., Zou Y. Molecular pharmacodynamics of PM02734 (elisidepsin) as single agent and in combination with erlotinib; synergistic activity in human non-small cell lung cancer cell lines and xenograft models. Eur J Cancer 2009, 45:1855-1864.
89. Lopez-Guerra M., Colomer D. NF-kappaB as a therapeutic target in chronic lymphocytic leukemia. Expert Opin Ther Targets 2010, 14:275-288.
90. Lorenzo H.K., Susin S.A., Penninger J., Kroemer G. Apoptosis inducing factor (AIF): a phylogenetically old, caspase-independent effector of cell death. Cell Death Differ 1999, 6:516-524.
91. Los M., Panigrahi S., Rashedi I., Mandal S., Stetefeld J., Essmann F., et al. Apoptin, a tumor-selective killer. Biochim Biophys Acta 2009, 1793:1335-1342.
92. Lu M., Lin S.C., Huang Y., Kang Y.J., Rich R., Lo Y.C., et al. XIAP induces NF-kappaB activation via the BIR1/TAB1 interaction and BIR1 dimerization. Mol Cell 2007, 26:689-702.
93. Ma J., Xin X., Meng L., Tong L., Lin L., Geng M., et al. The marine-derived oligosaccharide sulfate (MdOS), a novel multiple tyrosine kinase inhibitor, combats tumor angiogenesis both in vitro and in vivo. PLoS ONE 2008, 3:e3774.
94. Maddika S., Ande S.R., Panigrahi S., Paranjothy T., Weglarczyk K., Zuse A., et al. Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy. Drug Resist Updat 2007, 10:13-29.
95. Matsumoto S.S., Haughey H.M., Schmehl D.M., Venables D.A., Ireland C.M., Holden J.A., et al. Makaluvamines vary in ability to induce dose-dependent DNA cleavage via topoisomerase II interaction. Anticancer Drugs 1999, 10:39-45.
96. Mayer A.M., Glaser K.B., Cuevas C., Jacobs R.S., Kem W., Little R.D., et al. The odyssey of marine pharmaceuticals: a current pipeline perspective. Trends Pharmacol Sci 2010, 31:255-265.
97. Michels J., Johnson P.W., Packham G. Mcl-1. Int J Biochem Cell Biol 2005, 37:267-271.
98. Miller C.P., Ban K., Dujka M.E., McConkey D.J., Munsell M., Palladino M., et al. NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. Blood 2007, 110:267-277.
99. Miller J.H., Rouwe B., Gaitanos T.N., Hood K.A., Crume K.P., Backstrom B.T., et al. Peloruside A enhances apoptosis in H-ras-transformed cells and is cytotoxic to proliferating T cells. Apoptosis 2004, 9:785-796.
100. Miloslavich P., Diaz J.M., Klein E., Alvarado J.J., Diaz C., Gobin J., et al. Marine biodiversity in the Caribbean: regional estimates and distribution patterns. PLoS ONE 2010, 5:e11916.
101. Nakagawa R., Motoki K., Ueno H., Iijima R., Nakamura H., Kobayashi E., et al. Treatment of hepatic metastasis of the colon26 adenocarcinoma with an alpha-galactosylceramide, KRN7000. Cancer Res 1998, 58:1202-1207.
102. Natori T., Akimoto K., Motoki K., Koezuka Y., Higa T. Development of KRN7000, derived from agelasphin produced by Okinawan sponge. Nippon Yakurigaku Zasshi 1997, 110(Suppl 1):63P-68P.
103. Newman D.J., Cragg G.M. Natural products as sources of new drugs over the last 25years. J Nat Prod 2007, 70:461-477.
104. Nicholson B., Lloyd G.K., Miller B.R., Palladino M.A., Kiso Y., Hayashi Y., et al. NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent. Anticancer Drugs 2006, 17:25-31.
105. Noguchi Y., Makino T., Yoshikawa T., Nomura K., Fukuzawa K., Matsumoto A., et al. The possible role of TNF-alpha and IL-2 in inducing tumor-associated metabolic alterations. Surg Today 1996, 26:36-41.
106. Nowell P.C. The clonal evolution of tumor cell populations. Science 1976, 194:23-28.
107. O'Dwyer K., Maslak P. Azacitidine and the beginnings of therapeutic epigenetic modulation. Expert Opin Pharmacother 2008, 9:1981-1986.
108. Ogi T., Margiastuti P., Teruya T., Taira J., Suenaga K., Ueda K. Isolation of C11 cyclopentenones from two didemnid species, Lissoclinum sp. and Diplosoma sp. Mar Drugs 2009, 7:816-832.
109. Oh H., Jensen P.R., Murphy B.T., Fiorilla C., Sullivan J.F., Ramsey T., et al. Cryptosphaerolide, a cytotoxic Mcl-1 inhibitor from a marine-derived ascomycete related to the genus Cryptosphaeria. J Nat Prod 2010, 73:998-1001.
110. Ohmori Y., Schreiber R.D., Hamilton T.A. Synergy between interferon-gamma and tumor necrosis factor-alpha in transcriptional activation is mediated by cooperation between signal transducer and activator of transcription 1 and nuclear factor kappaB. J Biol Chem 1997, 272:14899-14907.
111. Pacheco M.M., Nishimoto I.N., Mourao Neto M., Mantovani E.B., Brentani M.M. Prognostic significance of the combined expression of matrix metalloproteinase-9, urokinase type plasminogen activator and its receptor in breast cancer as measured by Northern blot analysis. Int J Biol Markers 2001, 16:62-68.
112. Pan Y., Fang L., Fan H., Luo R., Zhao Q., Chen H., et al. Antitumor effects of a recombinant pseudotype baculovirus expressing apoptin in vitro and in vivo. Int J Cancer 2010, 126:2741-2751.
113. Park C., Jung J.H., Kim N.D., Choi Y.H. Inhibition of cyclooxygenase-2 and telomerase activities in human leukemia cells by dideoxypetrosynol A, a polyacetylene from the marine sponge Petrosia sp. Int J Oncol 2007, 30:291-298.
114. Park C., Kim G.Y., Kim G.D., Lee W.H., Cheong J.H., Kim N.D., et al. Suppression of U937 human monocytic leukemia cell growth by dideoxypetrosynol A, a polyacetylene from the sponge Petrosia sp., via induction of Cdk inhibitor p16 and down-regulation of pRB phosphorylation. Oncol Rep 2006, 16:171-176.
115. Park C., Kim G.Y., Kim W.I., Hong S.H., Park D.I., Kim N.D., et al. Induction of apoptosis by (Z)-stellettic acid C, an acetylenic acid from the sponge Stelletta sp., is associated with inhibition of telomerase activity in human leukemic U937 cells. Chemotherapy 2007, 53:160-168.
116. Park M.T., Lee S.J. Cell cycle and cancer. J Biochem Mol Biol 2003, 36:60-65.
117. Penesyan A., Kjelleberg S., Egan S. Development of novel drugs from marine surface associated microorganisms. Mar Drugs 2010, 8:438-459.
118. Pettit G.R., Cichacz Z.A., Gao F., Herald C.L., Boyd M.R., Schmidt J.M., et al. Isolation and structure of Spongistatin 1. J Org Chem 1993, 58:1302-1304.
119. Pettit G.R., Herald C.L., Leet J.E., Gupta R., Schaufelberger D.E., Bates R.B., et al. Antineoplastic agents. 168. Isolation and structure of axinohydantoin. Can J Chem 1990, 68:1621-1624.
120. Pettit G.R., McNulty J., Herald D.L., Doubek D.L., Chapuis J.C., Schmidt J.M., et al. Antineoplastic agents. 362. Isolation and X-ray crystal structure of dibromophakellstatin from the Indian Ocean sponge Phakellia mauritiana. J Nat Prod 1997, 60:180-183.
121. Pollack V.A., Alvarez E., Tse K.F., Torgov M.Y., Xie S., Shenoy S.G., et al. Treatment parameters modulating regression of human melanoma xenografts by an antibody-drug conjugate (CR011-vcMMAE) targeting GPNMB. Cancer ChemotherPharmacol. 2007, 60:423-435.
122. Prasad S., Ravindran J., Aggarwal B.B. NF-kappaB and cancer: how intimate is this relationship. Mol Cell Biochem 2010, 336:25-37.
123. Qin Z.H., Chen R.W., Wang Y., Nakai M., Chuang D.M., Chase T.N. Nuclear factor kappaB nuclear translocation upregulates c-Myc and p53 expression during NMDA receptor-mediated apoptosis in rat striatum. J Neurosci 1999, 19:4023-4033.
124. Radisky D.C., Radisky E.S., Barrows L.R., Copp B.R., Kramer R.A., Ireland C.M. Novel cytotoxic topoisomerase II inhibiting pyrroloiminoquinones from Fijian sponges of the genus Zyzzya. J Am Chem Soc 1993, 115:1632-1638.
125. Rashid M.A., Gustafson K.R., Boyd M.R. New cytotoxic N-methylated beta-carboline alkaloids from the marine ascidian Eudistoma gilboverde. J Nat Prod 2001, 64:1454-1456.
126. Ray A., Okouneva T., Manna T., Miller H.P., Schmid S., Arthaud L., et al. Mechanism of action of the microtubule-targeted antimitotic depsipeptide tasidotin (formerly ILX651) and its major metabolite tasidotin C-carboxylate. Cancer Res 2007, 67:3767-3776.
127. Rayasam G.V., Tulasi V.K., Sodhi R., Davis J.A., Ray A. Glycogen synthase kinase 3: more than a namesake. Br J Pharmacol 2009, 156:885-898.
128. Roskelley C.D., Williams D.E., McHardy L.M., Leong K.G., Troussard A., Karsan A., et al. Inhibition of tumor cell invasion and angiogenesis by motuporamines. Cancer Res 2001, 61:6788-6794.
129. Rothmeier A.S., Ischenko I., Joore J., Garczarczyk D., Furst R., Bruns C.J., et al. Investigation of the marine compound spongistatin 1 links the inhibition of PKCalpha translocation to nonmitotic effects of tubulin antagonism in angiogenesis. FASEB J 2009, 23:1127-1137.
130. Rothmeier A.S., Schneiders U.M., Wiedmann R.M., Ischenko I., Bruns C.J., Rudy A., et al. The marine compound spongistatin 1 targets pancreatic tumor progression and metastasis. Int J Cancer 2010, 127:1096-1105.
131. Sallam A.A., Ramasahayam S., Meyer S.A., El Sayed K.A. Design, synthesis, and biological evaluation of dibromotyrosine analogs inspired by marine natural products as inhibitors of human prostate cancer proliferation, invasion, and migration. Bioorg Med Chem 2010, 18:7446-7457.
132. Santoro M.G., Garaci E., Amici C. Prostaglandins with antiproliferative activity induce the synthesis of a heat shock protein in human cells. Proc Natl Acad Sci USA 1989, 86:8407-8411.
133. Scheuer P.J. Some marine ecological phenomena: chemical basis and biomedical potential. Science 1990, 248:173-177.
134. Schimmer A.D., Welsh K., Pinilla C., Wang Z., Krajewska M., Bonneau M.J., et al. Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell 2004, 5:25-35.
135. Schneiders U.M., Schyschka L., Rudy A., Vollmar A.M. BH3-only proteins Mcl-1 and Bim as well as endonuclease G are targeted in spongistatin 1-induced apoptosis in breast cancer cells. Mol Cancer Ther 2009, 8:2914-2925.
136. Schumacher M., Cerella C., Eifes S., Chateauvieux S., Morceau F., Jaspars M., et al. Heteronemin, a spongean sesterterpene, inhibits TNF alpha-induced NF-kappa B activation through proteasome inhibition and induces apoptotic cell death. Biochem Pharmacol 2010, 79:610-622.
137. Schwartz G.K., Shah M.A. Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol 2005, 23:9408-9421.
138. Schyschka L., Rudy A., Jeremias I., Barth N., Pettit G.R., Vollmar A.M. Spongistatin 1: a new chemosensitizing marine compound that degrades XIAP. Leukemia 2008, 22:1737-1745.
139. Shakoori A., Mai W., Miyashita K., Yasumoto K., Takahashi Y., Ooi A., et al. Inhibition of GSK-3 beta activity attenuates proliferation of human colon cancer cells in rodents. Cancer Sci 2007, 98:1388-1393.
140. Shen S., Zhang P., Lovchik M.A., Li Y., Tang L., Chen Z., et al. Cyclodepsipeptide toxin promotes the degradation of Hsp90 client proteins through chaperone-mediated autophagy. J Cell Biol 2009, 185:629-639.
141. Sogawa K., Sumida T., Hamakawa H., Yamada T., Matsumoto K., Matsuda M., et al. Inhibitory effect of a marine microalgal polysaccharide on the telomerase activity in K562 cells. Res Commun Mol Pathol Pharmacol 1998, 99:259-265.
142. Song J., Jeong W., Wang N., Lee H.S., Sim C.J., Oh K.B., et al. Scalarane sesterterpenes from the Sponge Smenospongia sp. J Nat Prod 2008.
143. Stehlik C., de Martin R., Kumabashiri I., Schmid J.A., Binder B.R., Lipp J. Nuclear factor (NF)-kappaB-regulated X-chromosome-linked IAP gene expression protects endothelial cells from tumor necrosis factor alpha-induced apoptosis. J Exp Med 1998, 188:211-216.
144. Sun X.M., Bratton S.B., Butterworth M., MacFarlane M., Cohen G.M. Bcl-2 and Bcl-xL inhibit CD95-mediated apoptosis by preventing mitochondrial release of Smac/DIABLO and subsequent inactivation of X-linked inhibitor-of-apoptosis protein. J Biol Chem 2002, 277:11345-11351.
145. Sutherland M.S., Sanderson R.J., Gordon K.A., Andreyka J., Cerveny C.G., Yu C., et al. Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates. J Biol Chem. 2006, 281:10540-10547.
146. Tang X., Li J., Xin X., Geng M. A new marine-derived sulfated polysaccharide from brown alga suppresses tumor metastasis both in vitro and in vivo. Cancer Biol Ther 2006, 5:1474-1480.
147. Thornberry N.A., Lazebnik Y. Caspases: enemies within. Science 1998, 281:1312-1316.
148. Tighe A., Ray-Sinha A., Staples O.D., Taylor S.S. GSK-3 inhibitors induce chromosome instability. BMC Cell Biol 2007, 8:34.
149. Till M., Prinsep M.R. 5-Bromo-8-methoxy-1-methyl-beta-carboline, an alkaloid from the New Zealand marine bryozoan Pterocella vesiculosa. J Nat Prod 2009, 72:796-798.
150. Tomimatsu S., Ichikura T., Mochizuki H. Significant correlation between expression of interleukin-1alpha and liver metastasis in gastric carcinoma. Cancer 2001, 91:1272-1276.
151. Trujillo J.I., Meyers M.J., Anderson D.R., Hegde S., Mahoney M.W., Vernier W.F., et al. Novel tetrahydro-beta-carboline-1-carboxylic acids as inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2). Bioorg Med Chem Lett 2007, 17:4657-4663.
152. Tuominen F.W., Kenney F.T. Inhibition of RNA-directed DNA polymerase from Rauscher leukemia virus by the 5'-triphosphate of cytosine arabinoside. Biochem Biophys Res Commun 1972, 48:1469-1475.
153. Ueno T., Toi M., Saji H., Muta M., Bando H., Kuroi K., et al. Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res 2000, 6:3282-3289.
154. van Loo G., Saelens X., van Gurp M., MacFarlane M., Martin S.J., Vandenabeele P. The role of mitochondrial factors in apoptosis: a Russian roulette with more than one bullet. Cell Death Differ 2002, 9:1031-1042.
155. Vilarino N. Marine toxins and the cytoskeleton: azaspiracids. FEBS J 2008, 275:6075-6081.
156. Villa F.A., Gerwick L. Marine natural product drug discovery: leads for treatment of inflammation, cancer, infections, and neurological disorders. Immunopharmacol Immunotoxicol 2010, 32:228-237.
157. Walker R.P., Thompson J.E., Faulkner D.J. Sesterpenes from Spongia idia. J Org Chem 1980, 45:4976-4979.
158. Wang C.Y., Mayo M.W., Korneluk R.G., Goeddel D.V., Baldwin A.S. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998, 281:1680-1683.
159. Warabi K., Hamada T., Nakao Y., Matsunaga S., Hirota H., van Soest R.W., et al. Axinelloside A, an unprecedented highly sulfated lipopolysaccharide inhibiting telomerase, from the marine sponge, Axinella infundibula. J Am Chem Soc 2005, 127:13262-13270.
160. Warabi K., Matsunaga S., van Soest R.W., Fusetani N. Dictyodendrins A-E, the first telomerase-inhibitory marine natural products from the sponge Dictyodendrilla verongiformis. J Org Chem 2003, 68:2765-2770.
161. Watanabe J., Natsume T., Kobayashi M. Comparison of the antivascular and cytotoxic activities of TZT-1027 (Soblidotin) with those of other anticancer agents. Anticancer Drugs 2007, 18:905-911.
162. Wei S.H., Dong K., Lin F., Wang X., Li B., Shen J.J., et al. Inducing apoptosis and enhancing chemosensitivity to gemcitabine via RNA interference targeting Mcl-1 gene in pancreatic carcinoma cell. Cancer Chemother Pharmacol 2008, 62:1055-1064.
163. Willis S.N., Chen L., Dewson G., Wei A., Naik E., Fletcher J.I., et al. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev 2005, 19:1294-1305.
164. Wonganuchitmeta S.N., Yuenyongsawad S., Keawpradub N., Plubrukarn A. Antitubercular sesterterpenes from the Thai sponge Brachiaster sp. J Nat Prod 2004, 67:1767-1770.
165. Xie Y., Liu L., Huang X., Guo Y., Lou L. Scalaradial inhibition of epidermal growth factor receptor-mediated Akt phosphorylation is independent of secretory phospholipase A2. J Pharmacol Exp Ther 2005, 314:1210-1217.
166. Xiong S., Pang H.D., Fan J., Ge F., Yang X.X., Liu Q.Y., et al. In vitro and in vivo antineoplastic activity of a novel bromopyrrole and its potential mechanism of action. Br J Pharmacol 2010, 159:909-918.
167. You J., Dai H., Chen Z., Liu G., He Z., Song F., et al. Trichoderone, a novel cytotoxic cyclopentenone and cholesta-7, 22-diene-3 beta, 5 alpha, 6 beta-triol, with new activities from the marine-derived fungus Trichoderma sp. J Ind Microbiol Biotechnol 2010, 37:245-252.
168. Zhao H., Liu H., Chen Y., Xin X., Li J., Hou Y., et al. Oligomannurarate sulfate, a novel heparanase inhibitor simultaneously targeting basic fibroblast growth factor, combats tumor angiogenesis and metastasis. Cancer Res 2006, 66:8779-8787.
169. Zheng L., Yan X., Han X., Chen H., Lin W., Lee F.S., et al. Identification of norharman as the cytotoxic compound produced by the sponge (Hymeniacidon perleve)-associated marine bacterium Pseudoalteromonas piscicida and its apoptotic effect on cancer cells. Biotechnol Appl Biochem 2006, 44:135-142.